Cardiovascular Disease and Cancer: Is There Increasing Overlap?
Purpose of Review
Cancer and cardiovascular disease are the leading causes of mortality in the USA. In this review, we highlight these shared disease pathways and provide a framework for a systems-based approach to reduce overall risk burden.
From traditional risk factors such as age and tobacco use to more recently recognized entities including clonal hematopoiesis, we are gaining insights into shared mechanisms. Because of these overlapping risks, providers on each level of patient care (primary care providers, cardiologists, oncologists) need to recognize and reduce these underlying risk factors.
There is significant overlap in the epidemiology and risk factors for the development of cardiovascular disease and cancer, providing opportunities for joint risk factor modification.
KeywordsCardio-oncology Cardiotoxicity Cancer
Compliance with Ethical Standards
Conflict of Interest
Logan Vincent declares that she has no conflict of interest.
Douglas Leedy declares that he has no conflict of interest.
Sofia Carolina Masri declares that she has no conflict of interest.
Richard K. Cheng has served as a consultant and participated on advisory boards for Alnylam Pharmaceuticals (modest) and Ionis/Akcea Pharmaceuticals (modest).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep. 2016;64(2):1–119.Google Scholar
- 4.Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011 Mar 1;123(8):933–44.PubMedCrossRefPubMedCentralGoogle Scholar
- 6.Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults--United States, 2005. MMWR: Morbidity and Mortality weekly report. 2009;58(16):421–6.Google Scholar
- 11.Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013; HHF. 0b013e318291329a.Google Scholar
- 18.Society AC. Cancer facts & figures 2018. American Cancer Society: Atlanta; 2018.Google Scholar
- 22.Garcia M, Jemal A, Ward E, et al. Global cancer facts & figures 2007, vol. 1. Atlanta: American cancer society; 2007. p. 52.Google Scholar
- 27.Prevention CfDCa. Consumption of cigarettes and combustible tobacco--United States, 2000–2011. MMWR Morb Mortal Wkly Rep. 2012;61:565.Google Scholar
- 28.Services UDoHaH. The health consequences of smoking—50 years of progress: a report of the Surgeon General, vol. 17. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.Google Scholar
- 33.Morris PB, Ference BA, Jahangir E, Feldman DN, Ryan JJ, Bahrami H, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66:1378–91.PubMedCrossRefPubMedCentralGoogle Scholar
- 67.FDA Drug Safety Communication. No increase in risk of cancer with certain blood pressure drugs—Angiotensin Receptor Blockers (ARBs), 15 July 2010; www.fda.gov/Drugs/DrugSafety/ucm257516.htm.
- 77.Weberpals J, Jansen L, van Herk-Sukel MPP, Kuiper JG, Aarts MJ, Vissers PAJ, et al. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis. Eur J Epidemiol. 2017;32:1019–31.PubMedCrossRefPubMedCentralGoogle Scholar
- 85.Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clinical Journal of the American Society of Nephrology. 2010 Mar 1;5(3):477–83.PubMedPubMedCentralCrossRefGoogle Scholar
- 87.Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–91.PubMedCrossRefPubMedCentralGoogle Scholar
- 95.Carter PR, Uppal H, Chandran S, Bainey KR, Potluri R. Algorithm for Comorbidities, Length of Stay and Mortality (ACALM) Research Unit. Patients with a diagnosis of hyperlipidaemia have a reduced risk of developing breast cancer and lower mortality rates: a large retrospective longitudinal cohort study from the UK ACALM registry. European Heart Journal 2017;38:3106Google Scholar
- 101.Preventing anthracycline cardiovascular toxicity with statins (PREVENT). https://clinicaltrials.gov/ct2/show/nct01988571. Accessed 1/22/2019.
- 102.Mellitus D. A major risk factor for cardiovascular disease: a joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation. 1999;100:1132–3.CrossRefGoogle Scholar
- 103.Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Phys Heart Circ Phys. 1992;263:H321–6.Google Scholar
- 114.Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Prev Biomark. 2002;11:1531–43.Google Scholar
- 121.Katsanos K, Tsianos E. The kidneys in inflammatory bowel disease. Ann Gastroenterol. 2002;15(1):41–52Google Scholar
- 134.•• Lancellotti P, Suter T, Lopez-Fernandez T, et al. Cardio-oncology services: rationale, organization, and implementation. A report from the ESC Cardio-Oncology council. Eur Heart J. 2018;00:1–8 A report from the European Society of Cardiology Cardio-Oncology council that provides justification for the existence of Cardio-Oncology services, provides options for how these services should be organized, and addresses their scope of practice. It emphasizes members of the Cardio-Oncology team and describes options for structuring these services across different care settings (i.e., clinic vs. community hospital vs. tertiary hospital). Google Scholar
- 136.•• Handy C, Quispe R, Pinto X, et al. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger. Circulation. 2018;138:727–34 Review article that evaluates opportunities for overlap in the prevention of cardiovascular and oncologic disease. It lays out the data for a relationship between common cancers and cardiovascular disease and possible targets for combining cardiovascular and oncologic screening. These include low-dose chest CT for coronary calcification and lung cancer, and mammography for breast cancer and breast arterial calcification. PubMedCrossRefPubMedCentralGoogle Scholar
- 138.Kemmeren JM, van Noord PA, Beijerinck D, Fracheboud J, Banga JD, van der Graaf Y. Arterial calcification found on breast cancer screening mammograms and cardiovascular mortality in women: the DOM Project. Doorlopend Onderzoek Morbiditeit en Mortaliteit. Am J Epidemiol. 1998;147:333–41.PubMedCrossRefPubMedCentralGoogle Scholar
- 139.Kemmeren JM, Beijerinck D, van Noord PA, Banga JD, Deurenberg JJ, Pameijer FA, et al. Breast arterial calcifications: association with diabetes mellitus and cardiovascular mortality. Work Prog Radiol. 1996;201:75–8.Google Scholar
- 145.• Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017;47:678–82 A review article exploring possible means of detecting and caring for cardiovascular disease and complications of oncologic diagnoses. The review encourages immediate cardiovascular risk assessment following every cancer diagnosis, and anticipation, monitoring, and treatment for cardiotoxicity. It also emphasizes the importance of long-term monitoring for cardiovascular complications given potential significant delay in development of cardiovascular complications. PubMedCrossRefPubMedCentralGoogle Scholar
- 147.• Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32:900–7 A review article summarizing the evidence for overlapping epidemiology for cardiovascular and oncologic disease and how cardiovascular disease may affect treatment of malignancies. It also addresses how cardiovascular disease may play a role in determining cancer outcomes. Finally, it touches on the potential for modeling of individually tailored cardiovascular risk in the setting of a cancer diagnosis. PubMedCrossRefPubMedCentralGoogle Scholar
- 148.Plana J, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.PubMedPubMedCentralCrossRefGoogle Scholar
- 151.• Armenian S, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. J Clin Oncol. 2016;34:1122–30 A retrospective cohort study to evaluate burden of cardiovascular disease in a large population of adult-onset cancer survivors. They found that rates of cardiovascular disease following cancer treatment were related to the number of cardiovascular risk factors and type of cancer. PubMedCrossRefPubMedCentralGoogle Scholar